T-knife Therapeutics luggage $110M to sharpen strong tumor cell remedy thrust into the clinic

Investors have flocked to T-knife Therapeutics, which has been using intention at stable tumors, an space exactly where cell therapies have struggled to perform as very well as they have in some blood cancers. Just final yr, the biotech lifted €66 million ($78 million) and now has reeled in a even more $110 million to help a multifront drive into scientific trials.

Berlin-centered T-knife was launched to establish on a long time of do the job to produce a transgenic mouse capable of facilitating the discovery of humanized T-cell receptors (TCRs). The do the job has provided T-knife a platform that leverages purely natural variety to generate higher-affinity human TCRs. An early validation test uncovered the mice created TCRs with higher affinity for human MAGE-1A antigen than TCRs from humans.

In a statement, Alex Mayweg, Ph.D., chairman of T-knife and taking care of director at Versant Ventures, identified as the platform “an stylish and differentiated strategy to determining potent, cancer-particular TCRs with normally optimized affinity and specificity profiles.” 

Fidelity Management led the series B with help from fellow new investors including LSP, Qatar Expense Authority and Casdin Cash. Current backers RA Cash Administration, Versant Ventures and Andera Associates also contributed.

Relevant: Versant, RA Cash tee up T-knife to implement TCRs to reliable tumors

T-knife will use the cash to commence enrolling individuals with MAGE-A1 good cancers in a stage 1/2 demo in the fourth quarter. Upcoming calendar year, T-knife plans to submit purposes to run scientific trials of other candidates. Charité University Clinic, just one of the groups driving T-knife, commenced a phase 1 demo of MAGE-A1-particular TCR-transduced T cells in various myeloma individuals past calendar year. The 12-subject trial is assessing the protection and tolerability of one escalating doses of the autologous T cells.

The clinical trials will start to show no matter if T-knife’s preclinical promise interprets into efficacy in individuals. Other groups have identified TCT-T mobile therapies as a far better way to go right after sound tumors than Car or truck-Ts, which battle to penetrate tumors, but T-knife and its backers see scope to increase on existing efforts by dialing up the affinity and specificity of the TCRs.